Hong Kong Adventist Hospital – Stubbs Road (HKAH-SR) has recently made a significant advancement in the treatment of prostate cancer by introducing a minimally invasive technique called Irreversible Electroporation (IRE). This innovative approach has already shown promising results, with the hospital successfully completing two cases without any post-surgical side effects. To further enhance the precision and effectiveness of prostate cancer treatments, HKAH-SR has also established a Robotic Surgery Center equipped with the latest fourth-generation Da Vinci robotic surgery system.
Prostate cancer is a significant health concern, particularly in Hong Kong, where it ranks as the third most prevalent cancer among men. Approximately 40% of diagnosed patients are identified at stages one or two, highlighting the importance of early detection and effective treatment options. Traditional methods, such as prostatectomy (surgical removal of the prostate) and radiation therapy, often involve whole-organ approaches. While these treatments can be effective, they can also lead to side effects that significantly impact a patient’s quality of life, including issues with urinary, sexual, and rectal functions.
In recent years, the medical community has increasingly explored focal therapies, which aim to preserve the organ while targeting and eliminating cancer cells. IRE is one such focal therapy that has gained attention for its precision and minimal side effects. The procedure involves inserting several electrode needles through the skin to surround the cancer cells. These needles then deliver electric currents that create pores in the cancer cell membranes, disrupting their internal balance and leading to cell death. Unlike other focal treatments that use heat or freezing, IRE is non-thermal and non-freezing, which helps preserve the integrity of surrounding critical structures and eliminates the risk of thermal spread.
The benefits of IRE are evident from the data. According to recent studies, IRE has a minimal severe side effect rate of only 4.1%, with no cases of urinary incontinence reported. Additionally, 90.1% of patients maintain their erectile function within 90 days post-operation. These statistics are particularly encouraging for patients who are concerned about the potential side effects of traditional treatments.
The U.S. Food and Drug Administration (FDA) has recognized the potential of IRE, approving it for prostate tissue ablation treatment in December 2024. The technology has also received CE certification from the European Union, further validating its safety and efficacy.
At HKAH-SR, the integration of robotic-assisted surgery with IRE represents a significant step forward in personalized care. The fourth-generation Da Vinci robotic surgery system allows surgeons to perform precise, minimally invasive procedures with enhanced dexterity and control. By combining the precision of robotic surgery with the targeted approach of IRE, doctors can tailor treatment plans to each patient’s specific circumstances, ensuring the best possible outcomes.
For example, consider a patient diagnosed with early-stage prostate cancer. Instead of opting for a traditional prostatectomy, which could result in long-term side effects, the patient might choose IRE. The procedure would involve the insertion of electrode needles to target the cancer cells while preserving the surrounding healthy tissue. The robotic surgery system would ensure that the needles are placed with pinpoint accuracy, minimizing the risk of complications and maximizing the effectiveness of the treatment.
The success of the first two IRE cases at HKAH-SR is a testament to the potential of this innovative approach. These cases not only demonstrate the minimal side effects associated with IRE but also highlight the hospital’s commitment to advancing medical technology and providing the best possible care for its patients.
In conclusion, the introduction of IRE at HKAH-SR marks a significant milestone in the treatment of prostate cancer. By combining the precision of robotic surgery with the targeted approach of IRE, the hospital is setting a new standard for personalized and minimally invasive care. For patients facing the challenge of prostate cancer, this innovative treatment offers a promising alternative with the potential to significantly improve their quality of life.
